ulcerative colitis

reshuffle pipeline target reorganize shift change
Biotech

Ose narrows focus to conserve cash at expense of wider pipeline

Ose Immunotherapeutics is prioritizing its lung cancer med Tedopi and its ulcerative colitis therapy lusvertikimab.
James Waldron Dec 9, 2025 9:41am
Golfer devastated after just barely missing a putt

AnaptysBio abandons rosnilimab for UC after phase 2 fail

Nov 10, 2025 10:05am
Cornucopia overflowing with produce

Odyssey saga continues with $213M series D

Sep 10, 2025 8:00am
Spilled martini on green background

Vedanta's live bacteria cocktail fails phase 2 colitis trial

Aug 13, 2025 1:48pm
acquisition merger arrows

AbbVie ends development of IL-1 asset in ulcerative colitis

Jul 31, 2025 12:32pm
airplane landing flight end land plane runway

Abivax aces phase 3 colitis trials as end of cash runway looms

Jul 23, 2025 6:30am